StockData
ANI Pharmaceuticals Inc logo

ANI Pharmaceuticals Inc (ANIP) stock

ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$69.99−0.90 (-1.27%)

Close on Nov 17, 2026Market cap $1.61BP/E 14.9Yield –

ANI Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

ANI Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $49.91M, down 7.4% year over year. For fiscal 2025 it was $51.66M, up 15.9% from the year before. Over ten years it grew 33.5% a year on average. The highest annual figure on record is $51.66M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$51.66M+15.9%
FY2024Dec 31, 2024$44.58M+30.0%
FY2023Dec 31, 2023$34.29M+53.6%
FY2022Dec 31, 2022$22.32M+96.3%
FY2021Dec 31, 2021$11.37M-28.9%
FY2020Dec 31, 2020$16.00M-19.2%
FY2019Dec 31, 2019$19.81M+28.7%
FY2018Dec 31, 2018$15.39M+69.7%
FY2017Dec 31, 2017$9.07M+212.1%
FY2016Dec 31, 2016$2.91M+1.1%
FY2015Dec 31, 2015$2.87M+7.3%
FY2014Dec 31, 2014$2.68M+56.4%
FY2013Dec 31, 2013$1.71M+47.8%
FY2012Dec 31, 2012$1.16M-97.4%
FY2011Dec 31, 2011$44.18M+11.3%
FY2010Dec 31, 2010$39.71M+190.2%
FY2009Dec 31, 2009$13.68M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$14.75M-10.8%
Q1 FY2026Mar 31, 2026$10.60M+0.3%
Q4 FY2025Dec 31, 2025$12.26M-26.3%
Q3 FY2025Sep 30, 2025$12.30M+21.5%
Q2 FY2025Jun 30, 2025$16.54M+126.6%
Q1 FY2025Mar 31, 2025$10.56M+0.5%
Q4 FY2024Dec 31, 2024$16.65M+68.7%
Q3 FY2024Sep 30, 2024$10.13M-8.9%
Q2 FY2024Jun 30, 2024$7.30M-1.1%
Q1 FY2024Mar 31, 2024$10.51M+77.4%
Q4 FY2023Dec 31, 2023$9.87M+89.0%
Q3 FY2023Sep 30, 2023$11.12M+45.2%
Q2 FY2023Jun 30, 2023$7.37M+77.0%
Q1 FY2023Mar 31, 2023$5.92M+12.3%
Q4 FY2022Dec 31, 2022$5.22M+66.3%
Q3 FY2022Sep 30, 2022$7.66M+211.8%
Q2 FY2022Jun 30, 2022$4.17M+48.5%
Q1 FY2022Mar 31, 2022$5.27M+77.7%
Q4 FY2021Dec 31, 2021$3.14M-14.7%
Q3 FY2021Sep 30, 2021$2.46M-16.4%
Q2 FY2021Jun 30, 2021$2.81M-7.6%
Q1 FY2021Mar 31, 2021$2.97M-53.2%
Q4 FY2020Dec 31, 2020$3.68M-21.3%
Q3 FY2020Sep 30, 2020$2.94M-41.0%
Q2 FY2020Jun 30, 2020$3.04M-47.4%
Q1 FY2020Mar 31, 2020$6.34M+45.1%
Q4 FY2019Dec 31, 2019$4.68M+34.3%
Q3 FY2019Sep 30, 2019$4.98M+6.7%
Q2 FY2019Jun 30, 2019$5.77M+12.4%
Q1 FY2019Mar 31, 2019$4.37M+108.0%
Q4 FY2018Dec 31, 2018$3.48M+31.3%
Q3 FY2018Sep 30, 2018$4.67M+77.2%
Q2 FY2018Jun 30, 2018$5.14M+137.1%
Q1 FY2018Mar 31, 2018$2.10M+29.9%
Q4 FY2017Dec 31, 2017$2.65M+1863.7%
Q3 FY2017Sep 30, 2017$2.63M+153.0%
Q2 FY2017Jun 30, 2017$2.17M–
Q1 FY2017Mar 31, 2017$1.62M–
Q4 FY2016Dec 31, 2016$135.00K–
Q3 FY2016Sep 30, 2016$1.04M–

More ANI Pharmaceuticals figures

See a number that looks wrong?